엔지켐생명과학

183490KOSDAQ

50.8 / 100

Reference Date: 2026-09-08

Financial Score19.5 / 40

News Sentiment16.3 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Enzychem Life Sciences focuses on global new drug development, API manufacturing, health functional foods, and bio-oil production. The company is advancing the development of EC-18, a treatment for chemotherapy-induced oral mucositis, and expanding into AI-driven drug discovery and DAC technology. Its API division exports over 40 products globally, while its health functional food segment offers immune-supporting products like 'LockFeed Immune'.

Number of Employees

116people

Average Salary

48.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.60Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-12.05Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

1.15Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼5.3% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼0.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -9.7% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 1Average Sentiment Score 65

Negative
엔지켐생명과학, 상반기 연결·별도 검토의견 ‘의견거절’
엔지켐생명과학의 상반기 재무제표에 대한 회계감사인의 의견거절로 인해 부정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 990Won52-week high 1,69952-week low 990

1-month return3.0Point

1m 0% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)2026-08-14
Neutral반기보고서 (2026.06)2026-08-14